CAMBRIDGE, Mass., Dec. 9, 2024
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a
clinical-stage biopharmaceutical company focused on
creating precisely targeted therapies for
clinically proven kinase targets in cancer, today announced the
appointment of Grant Bogle to its
Board of Directors.
"Grant's demonstrated success in leading the growth and
evolution of oncology biotechnology companies augments our Board as
we work towards a potential first approval from our pipeline of
novel kinase inhibitors in 2026," said James Porter, Ph.D., Chief Executive Officer at
Nuvalent. "We welcome his collaboration and insights in
navigating the transition from development to commercialization as
we prepare for anticipated pivotal data readouts from both of our
parallel-lead programs in 2025 and we build the additional
infrastructure needed to bring our therapies to patients with
cancer, if approved."
Mr. Bogle brings nearly four decades of proven leadership in
building and growing biotechnology companies to the Nuvalent Board.
Throughout his career, he has served in senior leadership roles at
several specialty pharmaceutical and biotechnology companies and
worked alongside oncologists as part of the leadership of US
Oncology, the largest network of community oncology practices in
the United States. He has a proven
track record of success in the field of oncology and has guided
numerous products from early-stage development to
commercialization. Most recently, Mr. Bogle was the Chief Executive
Officer at Epizyme, Inc., and oversaw the 2022 acquisition of the
company by Ipsen. Prior to that, Mr. Bogle was Senior Vice
President and Chief Commercial Officer of TESARO, which was
acquired by GlaxoSmithKline in 2018. Earlier, he served as Senior
Vice President of Pharmaceutical and Biotech Solutions at McKesson
Specialty Health/U.S. Oncology.
"Nuvalent has demonstrated an uncompromising commitment to
realizing transformational change for patients through the
development of molecules designed to address clear
physician-identified medical needs. Its patient-centric approach
has paved a direct path from discovery through clinical
development, and the company is now working to make its vision of
delivering a new generation of precisely targeted therapies
to patients with cancer a reality," said Mr. Bogle. "It is a
privilege to be joining the Board of Directors at such an exciting
time in the company's journey, and I look forward to working
alongside this team towards our shared mission of bringing positive
impact to as many patients as we can."
Mr. Bogle currently serves on the board of Myrobalan
Therapeutics and the American School for the Deaf in Hartford, CT. He previously served on the
Board of Epizyme prior to his appointment to CEO and functioned as
a member of the compensation committee. Mr. Bogle earned a B.A. in
Economics from Dartmouth College, an
M.B.A from Columbia University and was
a 2020 Fellow in the Advanced Leadership Initiative at Harvard University.
Nuvalent is currently enrolling patients in the global Phase 2
portions of the ARROS-1 clinical trial of zidesamtinib, its novel
ROS1-selective inhibitor, and the ALKOVE-1 clinical trial of
NVL-655, its novel ALK-selective inhibitor. The company expects to
report pivotal data from both trials in 2025. Additionally, the
company plans to initiate the Phase 3 global, randomized,
controlled ALKAZAR trial in the first half of 2025 to evaluate
NVL-655 versus the current standard of care, ALECENSA® (alectinib),
for the treatment of patients with TKI-naïve ALK-positive NSCLC.
Zidesamtinib and NVL-655 are designed with the aim to address the
clinical challenges of emergent treatment resistance, off-target
CNS adverse events, and brain metastases that may limit the use of
currently available kinase inhibitors. The company is also
enrolling patients in the Phase 1a/1b
HEROEX-1 trial evaluating NVL-330, its novel HER2-selective
inhibitor, for patients with HER2-altered NSCLC, and continues to
advance an active discovery pipeline.
About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a
clinical-stage biopharmaceutical company focused on creating
precisely targeted therapies for patients with cancer,
designed to overcome the limitations of existing therapies for
clinically proven kinase targets. Leveraging deep expertise in
chemistry and structure-based drug design, we develop innovative
small molecules that have the potential to overcome resistance,
minimize adverse events, address brain metastases, and drive more
durable responses. Nuvalent is advancing a robust pipeline with
investigational candidates for ROS1-positive, ALK-positive, and
HER2-altered non-small cell lung cancer, and multiple
discovery-stage research programs.
Forward-Looking Statements
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended, including,
without limitation, implied and express statements regarding
Nuvalent's strategy, business plans, and focus; the expected timing
of data announcements, clinical trial initiations and FDA product
approvals; the clinical development programs for zidesamtinib,
NVL-655 and NVL-330; the design and timing of the ALKAZAR trial;
the design and enrollment of Nuvalent's clinical trials, including
for ARROS-1 and ALKOVE-1 their intended pivotal
registration-directed design; the potential of Nuvalent's pipeline
programs, including zidesamtinib, NVL-655 and NVL-330; the
implications of data readouts and presentations; Nuvalent's
research and development programs for the treatment of cancer; and
risks and uncertainties associated with drug development. The words
"may," "might," "will," "could," "would," "should," "expect,"
"plan," "anticipate," "aim," "goal," "intend," "believe," "expect,"
"estimate," "seek," "predict," "future," "project," "potential,"
"continue," "target" or the negative of these terms and similar
words or expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Drug development and commercialization
involve a high degree of risk, and only a small number of research
and development programs result in commercialization of a product.
You should not place undue reliance on these statements or the
scientific data presented.
Any forward-looking statements in this press release are based
on management's current expectations and beliefs and are subject to
a number of risks, uncertainties, and important factors that may
cause actual events or results to differ materially from those
expressed or implied by any forward-looking statements contained in
this press release, including, without limitation: risks that
Nuvalent may not fully enroll its clinical trials or that
enrollment will take longer than expected; unexpected concerns that
may arise from additional data, analysis, or results obtained
during clinical trials; the risk that results of earlier clinical
trials may not be predictive of the results of later-stage clinical
trials; the risk that data from our clinical trials may not be
sufficient to support registration and that Nuvalent may be
required to conduct one or more additional studies or trials prior
to seeking registration of our zidesamtinib or NVL-655 product
candidates; risks that Nuvalent may not achieve the goals and
milestones set forth in its OnTarget 2026 operating plan; the
occurrence of adverse safety events; risks that the FDA may not
approve our potential products on the timelines we expect, or at
all; risks of unexpected costs, delays, or other unexpected
hurdles; risks that Nuvalent may not be able to nominate drug
candidates from its discovery programs; the direct or indirect
impact of public health emergencies or global geopolitical
circumstances on the timing and anticipated timing and results of
Nuvalent's clinical trials, strategy, and future operations,
including the ARROS-1, ALKOVE-1, ALKAZAR and HEROEX-1 trials; the
timing and outcome of Nuvalent's planned interactions with
regulatory authorities; and risks related to obtaining,
maintaining, and protecting Nuvalent's intellectual property. These
and other risks and uncertainties are described in greater detail
in the section entitled "Risk Factors" in Nuvalent's Quarterly
Report on Form 10-Q for the quarterly period ended September 30, 2024, as well as any prior and
subsequent filings with the Securities and Exchange Commission. In
addition, any forward-looking statements represent Nuvalent's views
only as of today and should not be relied upon as representing its
views as of any subsequent date. Nuvalent explicitly disclaims any
obligation to update any forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nuvalent-appoints-grant-bogle-to-board-of-directors-302325581.html
SOURCE Nuvalent, Inc.